Vadadustat Disease Interactions

Vadadustat is contraindicated in patients with uncontrolled hypertension as cases of hypertensive crisis including hypertensive encephalopathy and seizures have been reported. Patients with history of seizure disorders receiving this drug should be monitored closely and should contact their health care provider for premonitory symptoms or change in seizure frequency.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

Vadadustat increases the risk of arterial and venous thrombotic events, including major adverse cardiovascular events. Patients with cardiovascular or cerebrovascular disease are at increased risk. Avoid the use of this drug in patients with history of myocardial infarction, cerebrovascular events, or acute coronary syndrome within the 3 months prior to starting treatment.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

Vadadustat may cause hepatotoxicity. Liver enzymes and bilirubin should be measured prior to treatment initiation and monitored during treatment. This drug is not recommended in patients with cirrhosis, or active, acute liver disease.